Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

Completed

• Conditions: Brain Metastasis

• Registration Number: NCT02913534
• Lead Sponsor: Institut de Cancérologie de Lorraine

Brief Summary

The aim is to identify in patients with brain metastases the predictive factors of overall survival, survival without local recurrence and survival with progression-free brain metastases after complementary whole brain radiotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-03
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Status Verified: 2016-09
• Study First Submitted: 2016-09-22
• Study First Submitted QC: 2016-09-22
• Last Update Submitted: 2016-09-22
• Study First Posted: 2016-09-23
• Last Update Posted: 2016-09-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients with one to three brain metastases treated in our department with hypofractionated stereotactic radiotherapy (SRT) from March 2008 to February 2013.

Exclusion Criteria

• A patient record captured after February 2013.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	72 months

Trial Locations

Locations (1)

Institut de Cancerologie de Lorraine; 🇫🇷 Vandoeuvre-les-Nancy, France